Personalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Your Basket's Financial Footprint
Aggregate market capitalisation and investor takeaways for the provided basket.
- Large-cap dominance generally implies lower volatility and closer broad-market tracking, reducing idiosyncratic risk.
- Suitable as a core, long-term holding for diversification rather than a short-term speculative position.
- Expect steady, long-term value creation rather than rapid, short-term gains; growth may be more measured.
PSNL: $848.64M
PRME: $977.47M
EDIT: $348.89M
- Other
About This Group of Stocks
Our Expert Thinking
The healthcare industry is shifting from one-size-fits-all treatments to therapies designed for specific genetic profiles. Companies in this collection are pioneering technologies that target diseases at their molecular source, potentially offering more effective treatments with fewer side effects.
What You Need to Know
This portfolio includes companies at various stages of innovation—from diagnostic tools to therapeutic development. Consider this an aggressive growth component for your investments, as many firms are still developing commercial pathways for their technologies.
Why These Stocks
These companies were selected for their leadership in genomic sequencing, biomarker discovery, and targeted therapies like CRISPR gene editing. Recent regulatory approvals for gene-specific treatments and AI advancements in drug discovery provide significant growth catalysts.
Why You'll Want to Watch These Stocks
The DNA of Future Medicine
Personalized medicine is rewriting healthcare's rulebook. These companies are at the forefront of a revolution that could make traditional treatments obsolete while creating entirely new markets.
Breakthrough Momentum
Recent regulatory approvals for gene therapies are accelerating the path to market. As more personalized treatments gain validation, these pioneering companies could see rapid adoption and growth.
Beyond One-Size-Fits-All
Imagine treatments designed specifically for your genetic code. These companies are making this a reality, potentially capturing massive value as healthcare shifts toward precision therapies with better outcomes.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Streaming Power Dynamics Explained | Content Wars
The resolution of the content dispute between Disney and Google's YouTube TV highlights the critical interdependence of content creators and distributors. This dynamic creates an investment opportunity in companies that are central to the streaming ecosystem, from content production to platform delivery.
Jeep Hybrid Recall Overview: Market Shift Analysis
Stellantis is recalling nearly 113,000 Jeep plug-in hybrids because of a serious engine defect, creating potential investment opportunities. This theme focuses on competing automakers and aftermarket parts suppliers that may benefit from a shift in consumer confidence and repair needs.